New Venture Creation 2 (Launching a spin-out company) 31 Oct - 2 Nov 2018



Receive £50 reduction in the course fee if you also attended New Venture Creation 1 (First steps towards spinouts and start-up companies) in September 2018. 

Discount will be applied at invoicing stage.

Is this course right for me?

  • This course is for knowledge transfer professionals with at least 18 months’ technology transfer experience gained in an academic, public sector research or NHS innovation environment
  • A working knowledge of contracts and IP management will be assumed
  • It enables delegates to develop practical skills in scrutinising a business plan, understanding the different sources of finance available, critiquing and mentoring pitching. It will enable delegates to understand the key terminology in new venture creation, including term sheet and their consequences understanding the basics of company valuation, the role of directors, supporting the company post-incorporation. So, it’s likely to be of most value for those who are developing their case management skills and looking to embrace this aspect of KT
  • Those who have attended a PraxisAuril ‘core’ course (e.g. Fundamentals of Technology Transfer or Research Contracts) might find this to be a valuable next step, especially if they are seeking to develop practical hand-on skills in how to determine whether projects are suitable for new company formation and how to start a new company
  • Delegates might have significant experience in TT/KT, but little practical experience of new venture formation and may be looking to kick start this activity in their institution

Why should I attend this course?

  • Company creation is a key element in the mix of instruments that allow Universities to deliver impact from their funding inputs and research outputs
  • Forming new companies can be a key enabler of developing new technologies and priming them for the market place, and a key tool for the knowledge transfer professional
  • It can facilitate economic benefits including a financial return to inventors and their institutions whilst creating new jobs and services of benefit to the local economy and beyond
  • New ventures may enjoy symbiotic relationships with their parent institutions investing in further University research and securing rights to develop arising IP
  • There is increasing expectation that Universities and research institutes should be skilled at setting up actively managing their relationships with new ventures companies
  • Creating new ventures is a complex, challenging and immersive experience. This course gives a framework for knowing how to embrace this exciting challenge

What will I learn from the course?

  • Define what success in new venture creation looks like from a range of stakeholder perspectives
  • It looks at how to scrutinise and develop opportunities to investment readiness and beyond
  • It explores basic company valuation and the key terminology in new venture creation, including term sheet and their consequences
  • It explores how to develop a pitch to gain investment

Delegates will have the opportunity to hear from academic, technology transfer practitioners with experience in company formation, lawyers and venture capital investors. There will also be ample opportunity for networking with other delegates, the course team and other contributors.

PLEASE NOTE: There may be a requirement for delegates to undertake some pre-course work/reading before the course begins.

What makes this course different to others available in the sector?

PraxisAuril is able to deliver this training from the unique perspective of KE practitioners. We see the world from the same angle as you do!  We draw on a wide pool of experience and expertise from within the profession and build them into the course content, ensuring we are always delivering up to date, sector leading training and development.

The course has been updated in light of feedback from last time, to ensure that it continues to meet the needs of each of our delegates. The highly participative and interactive programme uses a new range of interactive techniques to engage delegates in an immersive, memorable and enjoyable learning experience.

View provisional programme

20% discount on group bookings

Make a 20% saving on course fees by registering five or more delegates from your organisation for this event.

The course fee includes:

  • Attendance at all lectures and workshops
  • Training and reference materials (electronic or otherwise)
  • Registration event (including buffet dinner & drinks*) on Wednesday 31 October 2018
  • Networking event (including buffet dinner & drinks*) on Thursday 1 November 2018
  • Morning and afternoon refreshments and lunch every day

* Please note that there is no reduction in the course fee if you choose not to attend the evening events.

View Venue, Accommodation & Further Information




You need to login to book events Login to book

12 ATTP Points

31st October - 2nd November


1 week 4 days left to book

Course Fee (Members £895) £ 1025.00

Meet the Speakers/Trainers

Dr. Stuart Wilkinson

Co-Course Director
Head, Knowledge Exchange and Impact Team, University of Oxford
Stuart Wilkinson is Head of the Knowledge Exchange and Impact Team in the Research Services office of the University of Oxford. Stuart's current role is to support the University's engagement and partnership with external organisations across the institution to maximise the impact of the research, including regional partners including the LEP. Previously Stuart worked as a consultant advising and training governments, companies and research organisations on technology development, intellectual property discovery, commercialisation strategy and business planning. Stuart also worked for Isis Innovation where he was responsible for evaluating, protecting and commercialising intellectual property in materials, engineering, energy and imaging technologies, including developing translational funding applications, business plans and negotiating investment for spin-out businesses. Stuart has a DPhil and MEng in BioMaterials and Materials Science from the University of Oxford.

Dr. Iain Thomas RTTP

Course Director
Head of Life Sciences, Cambridge Enterprise Ltd
Iain is Head of Cambridge Enterprise’s Life Sciences team at the University of Cambridge where he and his team work in fields as diverse as therapeutics, diagnostics, biofuels, IVF, epigenetics and agritech. CE’s portfolio of products includes alemtuzumab (Sanofi), breast cancer markers (Brevagen) and mouse touch screen chambers (Campden Instruments). Recent spin-outs include Morphogenix, Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics (sold to Janssen), Z-factor, Phoremost, and Storm Therapeutics. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the SBC and was the Cambridge lead for the Apollo Therapeutics Fund. Iain has been an active trainer for Praxis Courses since 2004.

Mr. Tony Hickson RTTP

Chief Business Officer, Cancer Research UK
Tony Hickson BSc, MBA, CLP, RTTP is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisAuril. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

Mairi Gibbs

Head of Operations, Oxford University Innovation
Dr Mairi Gibbs is Head of Operations at Oxford University Innovation (OUI). A member of OUI’s Strategic Team, she leads OUI’s operational activities across the business, including OUI’s post-deal alliance management function, patent and licence administration team, and information systems. Mairi is responsible for OUI’s process and standard legal documentation. She has particular interests in working with University colleagues to develop the University’s innovation framework to meet current and future needs, and in change management and professional development of technology transfer staff. Mairi is a member of Oxford’s Conflicts of Interest Committee and attends Oxford’s Intellectual Property Advisory Group. She has worked at OUI (formerly Isis Innovation) since 2002, and her extensive practical experience in technology transfer includes formation of spinout companies, licensing, academic outreach, patent portfolio management and prosecution, and management of technology transfer teams. Mairi has a PhD in Chemistry and spent some time in the fine chemicals industry before moving to tech transfer.

Dr. Victor Christou

Chief Executive, Cambridge Innovation Capital
Victor is Chief Executive at Cambridge Innovation Capital.
Victor has considerable experience on both sides of the investment table. In recent years he has focused his attention on technology investing. Immediately prior to CIC, Victor was at pan-European venture capital investors Wellington Partners, where he was a Venture Partner in the Tech Team. Before that Victor founded Opsys, an organic electronics business focusing on OLEDs and was a member of the team that sold Opsys to Cambridge Display Technology (now owned by Sumitomo Chemicals). Victor has a BSc and PhD in Chemistry from Imperial College, London and was a Sloan Fellow in the Graduate School of Business at Stanford University. In the early stages of his career, Victor was an academic at the University of California at Berkeley and then at the University of Oxford, where he was a Royal Society University Research Fellow and Junior Research Fellow at Balliol College. Victor was the Royal Society of Chemistry Entrepreneur of the Year in 2002.

Nina Searle

Associate, TLT LLP
Nina is an associate in TLT's Corporate team with over 10 years' experience advising local, national and international clients on mergers and acquisitions, venture capital and private equity investments. Nina's clients range from owner managers through to global corporates, and include various venture capital funds and private equity houses. She is a member of the firm's Technology, Media and Telecoms team, with particular experience of acting for universities, academics and entrepreneurs on spin out ventures.
Login to book